Sanofi loses bid to revive Lantus Solostar insulin-pen patents
In a win for Sanofi-competitor Viatris, Sanofi's attempt to keep its patent for the blockbuster insulin injection pen, Lantus SoloStar, has been rejected by the US Court of Appeals.
By Susan Decker, bloomberg
Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New Sanofi study is yet another win for blockbuster drug
For subscribers
